Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or -ultralow breast cancer.
Donald Patrick McDonnell, Ph.D., has been awarded the Endocrine Society’s John D. Baxter Prize for Entrepreneurship for discovering hormone therapies for treating breast and prostate cancer, the ...
An innovative organoid model mirrors the pancreas' complexity, generating all three key cell types to explore development and ...
Findings showed datopotamab deruxtecan reduced the risk of disease progression or death by 37% compared with chemotherapy.
The new study adds to growing evidence that measuring activated proteins is key to cancer therapy selection.Golden, CO, Feb. 10, 2025 (GLOBE ...
A study published in the Journal of Exposure Science and Environmental Epidemiology, summarized by News Medical, looked at the link between PFAS-contaminated drinking water and cancer incidence in ...
Verywell Health on MSN6d
A New 'Missile' Drug Is Approved To Treat the Most Common Breast Cancer TypeFact checked by Nick Blackmer The Food and Drug Administration (FDA) recently approved a new targeted chemotherapy drug for ...
Researchers found that moderate triclosan exposure is significantly linked to increased breast cancer risk, particularly in ...
– Updated overall survival (OS) results – a key secondary endpoint – reinforce the significant benefit of the Itovebi TM (inavolisib)-based regimen for patients with advanced PIK3CA-mutated ...
The US Food and Drug Administration (FDA) will soon decide on whether to expand the label of MSD’s Welireg (belzutifan) to include its use for the treatment of the rare cancer pheochromocytoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback